WELL Health’s headwinds are in the “rearview mirror”, analyst says

Stifel analyst Justin Keywood said in an April 23 update that management commentary from WELL Health Technologies (WELL Health Technologies Stock Quote, Chart, News, Analysts, Financials TSX:WELL) and HealWELL AI  points to 2025 headwinds moving into the “rearview mirror,” with improving sector valuations creating a better setup for both stocks.

Keywood said meetings with leaders across WELL’s group of companies increased his confidence in the direction of fundamentals. He said WELL still has a significant consolidation opportunity in Canadian primary and specialty care clinics, where it holds the No. 1 market share but only at about 1.5%, compared with roughly 55% consolidation in the U.S. WELL owns about 250 clinics today and has a pipeline of roughly 2,000 potential clinic targets.

“We believe as near-term catalysts play out for WELL/HEALWELL, valuation will re-rate more commensurate with broader sector strength as investors look past rearview headwinds,” Keywood said.

WELL reported 1.27-million patient visits in the first quarter of 2026, up 33% from 960,000 a year earlier, including 13% organic growth and 20% inorganic growth. Keywood said each WELL practitioner is now managing about 80 more patients per quarter than two years ago, reflecting the company’s use of technology and AI tools after acquisitions.

Keywood ascribed about $800-million in sum-of-the-parts value to WELL’s 252-clinic Canadian network. He said WELL often acquires underperforming clinics at zero to five per cent EBITDA margins, or losing money, and can move them to more than 10% margins within 12 to 18 months through AI tools, workflow changes and technology implementation.

On HealWELL, Keywood said the company is focused on free cash flow and deleveraging. HealWELL ended 2025 with $18.6-million in cash, and Keywood said a possible liquidation of its xAI position could generate more than $15-million, representing a potential near-term catalyst.

He estimated HealWELL’s net debt at $60-million, but said a $15-million cash injection, combined with a path to free-cash-flow neutrality by the fourth quarter of 2026 and new organic contract wins, would support further deleveraging.

On valuation, Keywood said WELL trades at about 1.0x sales, below virtual-care peers at 1.6x, while HealWELL trades at 2.4x sales versus pharma and life-sciences technology peers at 2.8x. WELL holds an approximately 30% economic interest in HealWELL, meaning improvements at HealWELL should also support WELL’s valuation.

Disclosure: Nick Waddell owns shares of WELL Health and the company is an annual sponsor of Cantech Letter

-30-